Vitamin D supplementation and neurofilament light chain in multiple sclerosis
Authors:
- 13 October 2018
- journal article
- research article
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 139 (2) , 172-176
Abstract
Objectives The effect of vitamin D supplementation on the disease course of multiple sclerosis (MS) is not established. Neurofilament light chain (NFL) is a sensitive marker of axonal degeneration. The aim of this study was to establish whether high‐dose vitamin D supplementation reduces serum levels of NFL. Materials and methods We have performed a 96 weeks placebo‐controlled randomized study of weekly supplementation with 20.000 IU vitamin D3 in 71 patients with relapsing remitting MS (RRMS). Serum levels of NFL were measured at baseline, week 48 and week 96 with a single molecule (Simoa) assay in 69 of these patients. Results Serum levels of 25‐hydroxyvitamin D more than doubled in the vitamin D group. Compared to placebo, vitamin D supplementation had no overall effect on the change in serum levels of NFL from baseline (p=0.93 at week 48 and p=0.56 at week 96). In the subgroup of patients not receiving disease‐modifying therapy, NFL decreased by 30.9% to week 48 and 32.6% to week 96 from baseline in the vitamin D group as compared to the placebo group (p=0.06 for both time points). Conclusion With a possible exception for patients not treated with disease‐modifying drugs, weekly supplementation with 20.000 IU vitamin D3 did not affect NFL levels in these RRMS patients.Keywords
Funding Information
- South Eastern Norway Regional Health Authority (2013006)
This publication has 34 references indexed in Scilit:
- Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatmentNeurology, 2012
- Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MSNeurology, 2012
- A randomised, double blind, placebo controlled trial with vitamin D3as an add on treatment to interferon β-1b in patients with multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2012
- A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosisNeurology, 2011
- Can vitamin D3 supplementation prevent bone loss in persons with MS? A placebo-controlled trialJournal of Neurology, 2011
- Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumabAnnals of Neurology, 2010
- Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosisAnnals of Neurology, 2010
- A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosisNeurology, 2010
- Serum 25-Hydroxyvitamin D Levels and Risk of Multiple SclerosisJAMA, 2006
- Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 1998